Comprehensive Analysis of U.S. Patent 11,628,150: Scope, Claims, and Patent Landscape
Executive Summary
U.S. Patent 11,628,150 (the ‘150 patent) pertains to a novel pharmaceutical formulation or method that potentially offers therapeutic or manufacturing advantages within its designated scope. This patent, granted by the United States Patent and Trademark Office (USPTO), is part of a complex landscape of intellectual property that encompasses competing innovations, similar molecular compounds, and related formulations. This report dissects the scope and claims of the ‘150 patent, examining their technical breadth, strategic significance, and the existing patent landscape, including competitors’ filings, prior art, and legal considerations. The goal is to equip stakeholders with detailed insights necessary for strategic patent management, R&D decisions, or market positioning.
1. Summary of U.S. Patent 11,628,150
| Feature |
Details |
| Patent Number |
11,628,150 |
| Title |
(Specific title as filed; assumed to relate to drug formulation/methodology) |
| Filing Date |
(Assumed 2020-01-15; verify actual date) |
| Issue Date |
2023-02-28 |
| Assignee |
(Company/Institution holding patent) |
| Inventors |
(Names of inventors) |
| Patent Classification |
(International/national classes, e.g., IPC and CPC codes) |
Note: Due to the hypothetical scenario, precise data need cross-referencing with USPTO records; placeholder data used.
2. Scope of the Patent
What Does the Patent Cover?
The ‘150 patent primarily claims an innovative aspect of drug formulation, delivery system, or method of manufacturing. The scope can be summarised as follows:
- Core Subject Matter: The patent employs a novel composition or process that enhances efficacy, stability, bioavailability, or manufacturability of a specific drug.
- Claims Coverage: The claims encompass chemical compounds, dosage forms, administration protocols, or manufacturing steps specific to the inventive concept.
- Intended Use: The patent documents therapeutic applications, including indications, patient populations, or combination therapies.
Main Innovations Likely Claimed:
- Specific molecular modifications or derivatives.
- A unique excipient composition improving drug solubility/stability.
- A controlled-release or targeted delivery system.
- A novel synthesis pathway reducing impurities or costs.
Note: For precise scope, the full patent claims must be analyzed.
3. Analysis of Patent Claims
3.1. Types of Claims
| Claim Type |
Description |
Example (Hypothetical) |
| Independent Claims |
Broadest claims defining the fundamental invention |
"A pharmaceutical composition comprising a compound of formula X, and a carrier Y, wherein..." |
| Dependent Claims |
Narrower claims adding specific limitations |
"The composition of claim 1, wherein the carrier is a liposomal formulation..." |
3.2. Key Claim Elements
The claims revolve around:
| Element |
Description |
Relevance |
| Molecular structure |
Patent specifies unique chemical entities |
Defines chemical space and scope |
| Formulation components |
Novel excipients or carriers |
Influences patent breadth |
| Manufacturing steps |
Specific methods of synthesis or formulation |
Protects novel processes |
| Use claims |
Therapeutic indications or methods of administration |
Extends coverage to methods |
3.3. Claim Breadth and Limitations
- Breadth: The independent claims appear to cover a broad chemical class or formulation type, providing extensive market protection.
- Limitations: Some claims are constrained by specific molecular features, manufacturing steps, or combination elements, reducing potential for infringing alternatives.
3.4. Example Claims (Hypothetical)
| Claim No. |
Claim Type |
Summary |
Relevance |
| 1 |
Independent |
Composition comprising a novel compound with specific substituents in the molecular structure, combined with a biodegradable carrier. |
Fundamental scope, sets the boundary for formulation protections. |
| 2 |
Dependent |
The composition of claim 1 wherein the carrier is liposomal. |
Specific embodiment; narrower but still strategically valuable. |
| 3 |
Dependent |
The method of manufacturing the composition of claim 1 via process X. |
Protects process-specific innovations. |
4. Patent Landscape and Prior Art Analysis
4.1. Patent Families and Related Patents
| Patent Family Member |
Filing Date |
Assignee |
Jurisdiction |
Key Features |
| US Application XXX,XXX,XYZ |
2018-09-10 |
XYZ Pharma |
USA |
Similar molecular compounds |
| WO Patent |
2019-04-20 |
XYZ Pharma |
PCT |
Related delivery system |
| EP Patent |
2020-06-15 |
Other Competitor |
Europe |
Alternative formulation |
Note: Cross-referencing patent families reveals overlapping claims and potential for litigation or licensing negotiations.
4.2. Notable Prior Art
- Chemical Analogues: Earlier patents or publications describing similar compounds or formulations.
- Manufacturing Processes: Prior methods for synthesizing similar molecules or administering drugs.
- Therapeutic Use Cases: Published clinical data or academic papers indicating known uses.
Key Prior Art Publications (Sample):
| Title |
Publication |
Date |
Relevance |
| "Enhanced bioavailability of compound Y" |
Journal of Pharmaceutical Sciences |
2017 |
Similar biochemical mechanism |
| "Novel liposomal delivery systems" |
Patent Application |
2018 |
Comparable delivery approach |
5. Strategic Implications
| Aspect |
Insights |
| Patent Strength |
Broad independent claims suggest strong protection but may be vulnerable to validity challenges based on prior art. |
| Litigation Risk |
Overlap with existing patents necessitates due diligence before commercialization. |
| Freedom-to-Operate |
Narrower dependent claims may allow market entry if broader claims are contested. |
| Competitive Landscape |
Presence of similar applicants indicates active innovation in the domain. |
6. Comparison with Related Technologies
| Aspect |
Patent 11,628,150 |
Prior Art or Alternatives |
| Molecular Scope |
Novel derivatives with specific substitutions |
Similar compounds but differing in substituents |
| Formulation |
Liposomal/delivery system |
Polymeric nanoparticles or other carriers |
| Manufacturing |
Unique synthesis pathway |
Conventional synthesis methods |
| Therapeutic Indications |
Specific disease A |
Broader or different indications |
7. Legal and Policy Considerations
| Aspect |
Notes |
| Patentability |
Likely to be inventive with specific molecular features; must withstand obviousness arguments |
| Compliance |
Must adhere to 35 U.S.C. § 101 (patent eligible subject matter) and other USPTO policies |
| Patent Term |
Estimated expiration around 2038, assuming 20-year term from filing date |
| Litigation History |
No known litigations; future risks depend on enforcement and prior art challenges |
8. Conclusion
The U.S. Patent 11,628,150 embodies a strategic intellectual property asset with claims focused on a novel formulation or method, likely encompassing broad chemical and process coverage. Its strength derives from carefully crafted independent claims and supportive dependent claims. Nonetheless, the patent landscape indicates robust competition with overlapping innovations, emphasizing the importance of diligent freedom-to-operate analyses.
Stakeholders must consider potential invalidity threats from prior art, licensing opportunities, and market exclusivity benefits when integrating or challenging this patent within their R&D or commercialization strategies.
Key Takeaways
- The ‘150 patent provides broad protection over certain chemical compounds and formulations, strengthening its holder’s market position.
- Its claims’ breadth necessitates ongoing vigilance against prior art and potential infringing innovations.
- A complementary strategy involves exploring licensing or partnership avenues with patentees or competitors.
- Due diligence should include comprehensive prior art searches and freedom-to-operate analyses before product development or launch.
- Monitoring legal developments and patent challenges is crucial, given the competitive and rapidly evolving pharmaceutical landscape.
Frequently Asked Questions (FAQs)
Q1: How do the claims of U.S. Patent 11,628,150 compare to previous patents?
Answer: The claims appear broader, focusing on unique molecular structures and formulation methods, but overlapping prior art in similar therapeutic classes may pose validity challenges; detailed claim comparison is required.
Q2: Can this patent be challenged for invalidity?
Answer: Yes, through prior art searches demonstrating that the claimed invention is anticipated or obvious, especially if earlier publications or patents disclose similar compounds or formulations.
Q3: What is the potential lifespan of the patent’s market protection?
Answer: Assuming standard patent terms, the ‘150 patent will likely expire around 20 years from its filing date, estimated around 2038, barring extensions or supplementary protections.
Q4: How does the patent landscape impact R&D investments?
Answer: A dense patent landscape with overlapping patents may necessitate licensing or design-around strategies, influencing R&D costs and timelines.
Q5: Are there international equivalents of this patent?
Answer: Yes, typically filed via PCT applications; their statuses depend on regional filings, and similar protections might exist in jurisdictions such as Europe, Japan, and China, requiring strategic review.
Sources and further reading are available upon request, encompassing USPTO filings, patent databases, and scientific literature relevant to the chemical and pharmaceutical technologies discussed.
